A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
for Hypercholesterolaemia
Sites in Flint, Troy +75 more locations
Sponsor: AstraZeneca
Sex: All·Age: 18 - 130
Code: NCT07619131·Phase 3·Recruiting·Listed Jun 2026